Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Equity (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Return on Equity for 4 consecutive years, with 2.26% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 157.0% to 2.26% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.26% through Dec 2025, up 157.0% year-over-year, with the annual reading at 2.52% for FY2025, 21.0% down from the prior year.
  • Return on Equity hit 2.26% in Q4 2025 for Axsome Therapeutics, up from 3.13% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.74% in Q3 2023 to a low of 5.05% in Q1 2025.
  • Historically, Return on Equity has averaged 2.4% across 4 years, with a median of 2.26% in 2025.
  • Biggest YoY gain for Return on Equity was 157bps in 2025; the steepest drop was -328bps in 2025.
  • Year by year, Return on Equity stood at 1.4% in 2022, then increased by 26bps to 1.04% in 2023, then crashed by -269bps to 3.83% in 2024, then soared by 41bps to 2.26% in 2025.
  • Business Quant data shows Return on Equity for AXSM at 2.26% in Q4 2025, 3.13% in Q3 2025, and 3.91% in Q2 2025.